This post was originally published on here
WARWICK, UK / ACCESS Newswire / February 13, 2026 / Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC)(“the Company”; “Moolec”), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced positive results from the crushing process of its U.S. GLASO1 safflower platform, confirming gamma-linolenic acid (“GLA”) concentrations of approximately 45%.
The results follow the successful completion of Moolec’s 2025 U.S. GLASO1 safflower campaign and represent a major operational milestone, validating the Company’s ability to deliver commercial-scale agricultural and industrial performance through its plant-engineered molecular farming platform.
Crushing Results Confirm Commercial-Scale Performance
Following harvest, safflower produced under the GLASO1 program was processed through standard U.S. crushing operations. Analysis confirmed:
-
~45% GLA concentration
-
Compatibility with existing U.S. agricultural and industrial infrastructure
These results confirm that the GLASO1 platform performs reliably through the crushing stage at commercial scale, a critical validation step for scalable ingredient production.
2025 GLASO1 U.S. Campaign Highlights
-
1,100 acres of engineered safflower cultivated across the United States
-
Average yield of approximately 2,200 lbs/acre, up from ~1,400 lbs/acre in 2024
-
57% year-over-year yield increase
-
Harvest performance materially exceeded internal forecasts
The 2025 campaign marked Moolec’s first successful large-scale expansion of the GLASO1 platform, transitioning from prior development and smaller-scale deployments to full commercial agricultural execution.
Strategic Positioning in the U.S. Nutrition & Supplements Market
The high GLA concentration achieved through the GLASO1 platform significantly strengthens Moolec’s positioning in the U.S. nutrition and dietary supplements market, where demand favors:
-
High-concentration functional lipids
-
Plant-engineered, traceable ingredients
-
Scalable production systems aligned with existing infrastructure
Early engagement with U.S.-based market participants supports the Company’s strategy of disciplined, execution-led growth anchored in validated performance rather than speculative scale-up.
“The U.S. GLASO1 platform has reached an inflection point,” said Alejandro Antalich, CEO at Moolec Science. Achieving approximately 45% GLA concentration at commercial scale confirms that our technology is not only scientifically differentiated, but operationally executable within existing U.S. agricultural and processing infrastructure.”
“We believe the approximately 45% GLA concentration achieved by GLASO1 places it among the highest-performing GLA-producing platforms reported at commercial scale. This achievement reflects disciplined execution and close collaboration with best-in-class U.S. operators across the agricultural and processing value chain. Together, we have successfully validated acreage expansion, harvest performance, and crushing operations at scale. Our focus now is to build on this foundation through disciplined growth and the conversion of this operational advantage into sustainable, recurring revenue,” concluded Antalich.
Execution-Led Growth Strategy
Moolec continues to prioritize:
-
Scaling platforms with demonstrated, repeatable performance
-
Leveraging existing U.S. agricultural infrastructure
-
Maintaining strict cost and capital discipline
-
Communicating progress through execution-driven milestones
The Company views the 2025 U.S. GLASO1 campaign and subsequent crushing results as a foundational step toward repeatable commercial-scale production and long-term value creation.
About Moolec Science SA
Moolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company’s diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 118 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker “MLEC.” For more information, please visit www.moolecscience.com and ir.moolecscience.com.
Forward Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Moolec Science’s Contacts:
Investor Relations inquiries: [email protected]
¹ Pat. US11/438,951 and US13/025,345
SOURCE: Moolec Science
View the original
on ACCESS Newswire
